Triple Negative Breast Cancer News and Research

RSS

CRISPR helps find difficult to detect cancer cells

Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.

15 Oct 2019

Insilico and CTFH team up to expedite first-in-class therapeutics using AI platform

Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program research collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd..

9 Oct 2019

Unique immune cell linked to remission in patients with triple negative breast cancer

A unique type of immune cell has been discovered in human breast tissue, and breast cancer patients with more of these cells are more likely to survive, finds new research from the Francis Crick Institute and King's College London.

From The Francis Crick Institute 9 Oct 2019

Novel drug may be the answer in battling resistance in aggressive breast cancer

Breast cancer is one of the most frequently diagnosed cancers in women across the globe. It represents one in four of all cancers in women. The survival rates for breast cancer vary across the globe, but when it comes to the metastatic or advanced breast cancer type, it is currently incurable, but there are many treatments available.

7 Oct 2019

Potential metabolism target could slow or prevent breast cancer metastasis

Cancer cells - especially the more aggressive ones - seem to have an ability to change. It's how they evade treatment and spread throughout the body.

4 Oct 2019

Adding local anesthetics can improve treatment for incurable breast cancer, melanoma

A new study examined the effects of local anesthetics combined with standard chemotherapy for treatment of incurable triple-negative breast cancer, as well as melanoma.

3 Oct 2019

Roswell Park moving three-pronged immunotherapy strategy forward with support from DoD grant

A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a U.S. Department of Defense grant to Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Rustum Family Professor for Molecular Therapeutics and Translational Research at the Buffalo, N.Y.-based cancer center.

18 Sep 2019

Cell adhesion protein promotes metastasis in breast cancer, study reveals

Researchers at the Johns Hopkins Kimmel Cancer Center discovered that a cell adhesion protein, E-cadherin, allows breast cancer cells to survive as they travel through the body and form new tumors, a process termed metastasis.

From Johns Hopkins Medicine 11 Sep 2019

Genetic testing may help patients with metastatic breast cancer

Breast cancer is a condition wherein the cells in the breast grow uncontrollably. Breast cancer can spread to the other parts of the body, termed as metastatic breast cancer. It is one of the most aggressive and potentially deadly types of cancer.

10 Sep 2019

Study seeks to better understand, treat neuropathy in black women with breast cancer

Researchers at Indiana University School of Medicine have launched a new, unique study recruiting black women with breast cancer designed to better understand and treat neuropathy, a side effect from chemotherapy.

10 Sep 2019

Age affects efficacy of immunotherapy treatment for breast cancer, preclinical study reveals

Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.

8 Sep 2019

Nab-Paclitaxel drug combo reduces risk of breast cancer recurrence

A recent large German study has shown that a new combination therapy for breast cancer treatment leads to a lowered risk of the disease coming back. A commentary on this landmark clinical trial has been published in the latest issue of the Journal of Clinical Oncology by the researchers Masey Ross and Charles Geyer Jr. from the VCU Massey Cancer Center. The commentary was titled, “Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?”

27 Aug 2019

Super-powered immune cells to attack tumors

Ground-breaking immune therapy promises to deliver vital evidence in the fight against cancer as researchers from the Centre for Cancer Biology open a new clinical trial using genetically engineered immune cells to treat solid cancers.

23 Aug 2019

New model developed to optimize and personalize radiotherapy for cancer patients

A personalized approach to cancer treatment has become more common over the last several decades, with numerous targeted drugs approved to treat particular tumor types with specific mutations or patterns.

22 Aug 2019

Roswell Park receives more than $15 million in grants for cancer research

Roswell Park Comprehensive Cancer Center researchers have received more than a dozen recent grant awards totaling more than $15.4 million.

14 Aug 2019

Electromagnetic fields may prevent spread of breast cancer cells, study finds

Electromagnetic fields might help prevent some breast cancers from spreading to other parts of the body, new research has found.

8 Aug 2019

Women of color may face elevated risks of developing triple-negative breast cancer

A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, shows that women of color and young women may face elevated risks of developing triple-negative breast cancers, which are often aggressive and do not respond to hormone therapy or targeted therapy.

8 Jul 2019

3D breast tumor models may improve drug discovery and testing

Dr. Hossein Tavana, an associate professor of biomedical engineering at The University of Akron, has received a grant of $1.13 million from the prestigious National Cancer Institute to further develop 3D tumor models of triple-negative breast cancer -- which may improve drug testing and lead to the discovery of new, more effective anticancer drugs.

2 Jul 2019

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Researchers at the Bellvitge Biomedical Research Institute, with the participation of collaborators from the Baylor College of Medicine and the University Institute of Oncology of Asturias, publish today in Cancer Research a study where they relate the high number of copies of a chromosomal region with the appearance of resistance to a chemotherapeutic drug.

19 Jun 2019

First clinical test could enable personalized prognosis for triple-negative breast cancer patients

A personalized prognosis for patients diagnosed with triple-negative breast cancer was the goal of a new study by Katherine Varley, PhD, researcher at Huntsman Cancer Institute and assistant professor of oncological sciences at the University of Utah.

13 Jun 2019